ASCENDIS PHARMA

Serial Number 79225147
Registration 6630735
700

Registration Progress

Application Filed
Oct 11, 2017
Under Examination
Approved for Publication
Nov 16, 2021
Published for Opposition
Nov 16, 2021
Registered
Feb 1, 2022

Trademark Image

ASCENDIS PHARMA

Basic Information

Serial Number
79225147
Registration Number
6630735
Filing Date
October 11, 2017
Registration Date
February 1, 2022
Published for Opposition
November 16, 2021
Drawing Code
3000

Status Summary

Current Status
Active
Status Code
700
Status Date
Feb 1, 2022
Registration
Registered
Classes
005 042 045

Rights Holder

Ascendis Pharma A/S

99
Address
Tuborg Boulevard 5
DK-2900 Hellerup
DK

Ownership History

Ascendis Pharma A/S

Original Applicant
99
DK-2900 Hellerup DK

Ascendis Pharma A/S

Owner at Publication
99
DK-2900 Hellerup DK

Ascendis Pharma A/S

Original Registrant
99
DK-2900 Hellerup DK

Legal Representation

Attorney
Eric T. Fingerhut

USPTO Deadlines

Next Deadline
909 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-02-01)
Due Date
February 01, 2028
Grace Period Ends
August 01, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

50 events
Date Code Type Description Documents
Aug 1, 2022 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Jul 13, 2022 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jul 13, 2022 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
May 1, 2022 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Feb 1, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 24, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Nov 23, 2021 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Nov 16, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 16, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 28, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Oct 27, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 27, 2021 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Oct 27, 2021 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Oct 13, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 12, 2021 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Oct 12, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 12, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 9, 2021 CNFR R FINAL REFUSAL WRITTEN Loading...
Jul 9, 2021 GNFR O FINAL REFUSAL E-MAILED Loading...
Jul 9, 2021 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Jun 10, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 16, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 15, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 15, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Mar 15, 2021 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Mar 15, 2021 EWOR I TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Loading...
Mar 15, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Mar 15, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Mar 15, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 15, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Mar 15, 2021 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Loading...
Mar 15, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Mar 15, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Mar 15, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 15, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 14, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 14, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 14, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 18, 2020 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Jun 3, 2020 ALIE A ASSIGNED TO LIE Loading...
Nov 21, 2019 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Jul 5, 2019 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Jun 19, 2019 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Jun 19, 2019 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
May 9, 2019 RCSC S REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED Loading...
Oct 19, 2018 CNSL R SUSPENSION LETTER WRITTEN Loading...
Oct 19, 2018 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Oct 19, 2018 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Oct 1, 2018 DMCC I DATA MODIFICATION COMPLETED Loading...
Sep 28, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
First Use Anywhere: 0
First Use in Commerce: 0
Class 045
Licensing of industrial property; legal services
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of the turquoise word "ASCENDIS" under which is the grey word "PHARMA" next to a polygon broken by a white curved band in which the top is turquoise and the bottom is blue.
Color Claim
The color(s) turquoise, grey, white and blue is/are claimed as a feature of the mark.

Classification

International Classes
005 042 045

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMA"